Lipogrid, Oculus Innovative Sciences join forces to develop and market topical drug delivery formulations

Oculus Innovative Sciences Inc. and Lipogrid Company of Sweden announced they finalized a strategic collaborative agreement to develop and market topical drug delivery solutions, according to a press release.

The drug delivery formulations will be developed and marketed by Oculus and modeled from Lipogrid Technology. Lipogrid, used to treat skin disorders, is a lipid structural matrix of solid lipid particles and vesicles containing phospholipids, ceramides, fatty acids and cholesterol-type stabilizers with a delivery ability to build blocks to the dermis and protect the skin.

“We’ve studied the market extensively in terms of identifying a delivery mechanism that would increase the efficacy of our skin technologies. The Lipogrid Technology is one of the most advanced and safest in the world and we look forward to harnessing this technology to amplify skin penetration and improve patient outcomes worldwide,” IntraDerm Pharmaceuticals president, Oculus’ dermatology division, Jeffrey Day said in the release.

Lipogrid’s first prescription product received FDA 510(k) clearance in November 2015, according to the release.